세계의 멀티오믹스 시장 : 예측 - 유형별, 제품 및 서비스별, 기술별, 용도별, 최종 사용자별, 지역별 분석(2032년까지)

According to Stratistics MRC, the Global Multiomics Market is accounted for $3.2 billion in 2025 and is expected to reach $9.1 billion by 2032 growing at a CAGR of 15.9% during the forecast period. Multiomics is the integrated analysis of multiple "omics" data sets genomics, proteomics, transcriptomics, metabolomics, and more to gain a comprehensive understanding of biological systems. By aggregating diverse molecular layers, multiomics enables precise disease profiling, biomarker discovery, and targeted therapeutic development. It enhances data-driven decision-making across sectors such as precision medicine, diagnostics, and drug development.

Market Dynamics:

Driver:

Rise in precision medicine & personalized therapies

Multiomics provides the comprehensive molecular insights necessary to enable this personalized approach by integrating genomic, transcriptomic, proteomic, and metabolomic data to create detailed patient profiles. This integrated analysis allows healthcare professionals to identify specific disease mechanisms, predict treatment responses, and develop targeted therapeutic interventions. Furthermore, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions has intensified the demand for personalized treatment solutions, driving significant investments from both private and public sectors in multiomics research and development.

Restraint:

Lack of standardized analytical pipelines

The absence of standardized frameworks for data integration and interpretation continues to pose significant challenges for the multiomics market, limiting widespread adoption and reproducibility of research findings. Different omics datasets possess varying formats and structures, making seamless integration extremely complex and time-consuming for researchers. Additionally, the complexity of developing robust computational pipelines for multiomics analysis, combined with the high costs associated with specialized equipment and highly skilled personnel, creates substantial barriers for smaller research organizations and limits market penetration.

Opportunity:

Integration of AI/ML in multiomics data analysis

AI algorithms excel at integrating and analyzing vast datasets from various omics fields, enabling faster identification of disease subtypes, drug targets, and biomarkers while accelerating drug discovery processes. Cloud computing platforms are transforming how researchers handle large and complex multiomics datasets, providing scalable and cost-effective solutions for data storage and analysis. Advanced AI-driven predictive models can identify individuals at risk for specific diseases and predict treatment responses, facilitating the development of more effective personalized therapies and improving diagnostic accuracy across multiple healthcare applications.

Threat:

Risk of data breach or cybersecurity incidents

Stringent regulatory requirements such as GDPR in the European Union and HIPAA in the United States impose complex compliance obligations for collecting, storing, and sharing personal genomic and molecular data. The increasing interconnectedness of research networks and cloud-based platforms expands the attack surface for potential cyber threats. Data breaches involving multiomics information could have far-reaching consequences, including identity theft, discrimination, and loss of patient trust.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated multiomics research and applications, demonstrating the technology's critical role in understanding viral pathogenesis and host immune responses. Researchers utilized integrated multiomics approaches to profile plasma proteins, metabolites, and cellular transcripts from COVID-19 patients, revealing comprehensive molecular landscapes that single omics approaches could not capture. These studies identified 84 potentially active compounds for COVID-19 treatment and led to the discovery of six candidate drugs through computational analysis. Additionally, the pandemic highlighted multiomics' superior ability to detect viral entry pathways and complement system activation, providing crucial insights for therapeutic intervention strategies.

The bulk multiomics segment is expected to be the largest during the forecast period

The bulk multiomics segment is expected to account for the largest market share during the forecast period due to its widespread adoption in large-scale population studies, drug discovery initiatives, and comprehensive disease profiling applications. This approach remains the standard in multiomics workflows because of its cost-effectiveness compared to single-cell alternatives and the availability of well-established analytical tools and protocols. Additionally, research institutions and pharmaceutical companies prefer bulk multiomics for conducting extensive genomic studies and biomarker discovery programs, as it provides reliable results across diverse patient populations.

The precision medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the precision medicine segment is predicted to witness the highest growth rate, driven by multiomics data's unique ability to customize treatments based on individual patient molecular characteristics, resulting in more effective and personalized healthcare outcomes. This approach combines genomics, proteomics, metabolomics, and other molecular data layers to provide deeper understanding of disease mechanisms and identify specific therapeutic targets by analyzing root causes of diseases and predicting patient responses to different treatments. Furthermore, the growing recognition that traditional one-size-fits-all treatment approaches are inadequate for complex diseases continues to drive investment and research.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its robust research infrastructure, substantial investments in healthcare and biotechnology R&D, and strong support from both government and private sector funding initiatives. The region benefits from the presence of major life science companies, including Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which drive continuous innovation in multiomics approaches and technologies. The FDA's supportive regulatory environment for biomarker-guided drug development, combined with the region's advanced healthcare infrastructure and focus on personalized medicine, reinforces North America's dominant position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by increasing investments in life sciences research, a rapidly expanding number of biotechnology startups, and substantial improvements in healthcare infrastructure, particularly in key markets like China, Japan, and India. Government initiatives across the region actively promote biotechnology growth through comprehensive policies such as India's National Development Programmes and Sustainable Development Goals, which specifically support biotech development and biomanufacturing capabilities. Moreover, the region's growing prevalence of various diseases has intensified focus on novel drug discovery applications, with countries like China emerging as leaders in multiomics research through companies like BGI Group and substantial investments in genomics research and precision medicine initiatives. The combination of supportive regulatory environments, increasing healthcare awareness, and strategic government backing positions Asia Pacific as the fastest-growing regional market

Key players in the market

Some of the key players in Multiomics Market include 10x Genomics, Agilent Technologies, Becton, Dickinson and Company (BD), BGI Genomics, Bio-Rad Laboratories, Bio-Techne Corporation, Bruker, Danaher Corporation, Illumina, Mission Bio, NanoString Technologies, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Revvity, QIAGEN, Roche, Standard BioTools, Shimadzu Corporation, Thermo Fisher Scientific, and Human Longevity, Inc.

Key Developments:

In June 2025, Illumina, Inc. announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

In August 2024, Agilent announced a cooperation agreement with Sangon Biotech to advance nucleic acid research, with particular focus on promoting development in synthetic biology and multi-omics.

In January 2024, BD announced collaboration with Hamilton to develop automated applications and robotics-compatible reagent kits to enable greater standardization in large-scale single-cell multiomics experiments.

Types Covered:

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Epigenomics
• Lipidomics
• Microbiomics

Product & Services:

• Instruments
• Consumables
• Software & Analytics Platforms
• Services

Technologies Covered:

• Single-Cell Multiomics
• Bulk Multiomics
• Spatial Multiomics

Applications Covered:

• Drug Discovery & Development
• Precision Medicine
• Biomarker Discovery
• Clinical Diagnostics
• Agrigenomics
• Personalized Nutrition
• Environmental Research
• Microbiome Analysis
• Other Applications

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Clinics
• CROs & CDMOs
• Diagnostic Laboratories
• Agrigenomics Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Multiomics Market, By Type

• 5.1 Introduction
• 5.2 Genomics
• 5.3 Transcriptomics
• 5.4 Proteomics
• 5.5 Metabolomics
• 5.6 Epigenomics
• 5.7 Lipidomics
• 5.8 Microbiomics

6 Global Multiomics Market, By Product & Service

• 6.1 Introduction
• 6.2 Instruments
  • 6.2.1 Sequencing Instruments
  • 6.2.2 Mass Spectrometers
  • 6.2.3 Chromatography Systems
  • 6.2.4 Microarrays
• 6.3 Consumables
  • 6.3.1 Reagents & Kits
  • 6.3.2 Assay Kits
  • 6.3.3 Sample Preparation Kits
• 6.4 Software & Analytics Platforms
  • 6.4.1 Data Integration & Visualization Tools
  • 6.4.2 AI/ML Platforms
• 6.5 Services
  • 6.5.1 Multiomics Data Analysis
  • 6.5.2 Custom Services
  • 6.5.3 Contract Research Services

7 Global Multiomics Market, By Technology

• 7.1 Introduction
• 7.2 Single-Cell Multiomics
• 7.3 Bulk Multiomics
• 7.4 Spatial Multiomics

8 Global Multiomics Market, By Application

• 8.1 Introduction
• 8.2 Drug Discovery & Development
• 8.3 Precision Medicine
• 8.4 Biomarker Discovery
• 8.5 Clinical Diagnostics
• 8.6 Agrigenomics
• 8.7 Personalized Nutrition
• 8.8 Environmental Research
• 8.9 Microbiome Analysis
• 8.10 Other Applications

9 Global Multiomics Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical & Biotechnology Companies
• 9.3 Academic & Research Institutes
• 9.4 Hospitals & Clinics
• 9.5 CROs & CDMOs
• 9.6 Diagnostic Laboratories
• 9.7 Agrigenomics Companies
• 9.8 Other End Users

10 Global Multiomics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 10x Genomics
• 12.2 Agilent Technologies
• 12.3 Becton, Dickinson and Company (BD)
• 12.4 BGI Genomics
• 12.5 Bio-Rad Laboratories
• 12.6 Bio-Techne Corporation
• 12.7 Bruker
• 12.8 Danaher Corporation
• 12.9 Illumina
• 12.10 Mission Bio
• 12.11 NanoString Technologies
• 12.12 Oxford Nanopore Technologies
• 12.13 Pacific Biosciences (PacBio)
• 12.14 Revvity
• 12.15 QIAGEN
• 12.16 Roche
• 12.17 Standard BioTools
• 12.18 Shimadzu Corporation
• 12.19 Thermo Fisher Scientific
• 12.20 Human Longevity, Inc.